Gilead Sciences, Inc. (ETR:GIS)
Germany
· Delayed Price · Currency is EUR | Market Cap | 131.11B |
| Revenue (ttm) | 27.77B |
| Net Income (ttm) | 463.63M |
| Shares Out | n/a |
| EPS (ttm) | 0.37 |
| PE Ratio | 282.78 |
| Forward PE | n/a |
| Dividend | 2.85 (2.73%) |
| Ex-Dividend Date | Mar 14, 2025 |
| Volume | 1,474 |
| Average Volume | 1,596 |
| Open | 103.06 |
| Previous Close | 102.98 |
| Day's Range | 102.68 - 104.42 |
| 52-Week Range | 57.29 - 104.42 |
| Beta | 0.20 |
| RSI | 74.96 |
| Earnings Date | Feb 3, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca...
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease
NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry Cr...
How Is The Market Feeling About Gilead Sciences?
Gilead Sciences's (NYSE: GILD) short percent of float has fallen 8.91% since its last report. The company recently reported that it has 22.93 million shares sold short , which is 1.84% of all regular...
Gilead (GILD) Advances HIV Prevention Drug Lenacapavir with FDA Submission
Gilead (GILD) Advances HIV Prevention Drug Lenacapavir with FDA Submission
Gilead Sciences Inc (GILD) Advances HIV Prevention with FDA Acceptance of Lenacapavir NDA
Gilead Sciences Inc (GILD) Advances HIV Prevention with FDA Acceptance of Lenacapavir NDA
Arcus Biosciences Shares Are Down Today: What's Going On?
Arcus Biosciences Inc. (NYSE: RCUS) shares traded lower Tuesday after the company announced a $150 million common stock offering. What To Know: The financing is expected to support ongoing trials, in...
Gilead opts out of deal for Arcus cancer therapy
Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank
Calls of the Day: Gilead Sciences and Merck
The Investment Committee debate the Calls of the Day in two biotech names.
Calls of the Day: Gilead Sciences and Merck
The Investment Committee debate the Calls of the Day in two biotech names.
Gilead nabs priority review for twice yearly version of HIV med Sunlenca
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...
Dutch cancer patients forced to wait for drug pricing dispute resolution
The Dutch healthcare institute has called out drug manufacturers for allegedly withholding information. A spokesperson for Gilead told Euractiv they already submitted a comprehensive dossier.
Josh Brown's best stocks
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his favorite stocks in the market right now.
Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Thursday. Shares of Robinhood Markets, Inc . (NASDAQ: HOOD) rose sharply during Thursday's session after the company re...
Asia Markets Mixed, Europe Hits Highs On Earnings; Oil Dips On Russia-Ukraine Peace Talks - Global Markets Today While US Slept
On Wednesday, U.S. markets closed mixed, with the S&P 500 declining as unexpectedly high inflation data heightened concerns about delayed Fed rate cuts. Nvidia and Amazon weakened, weighing on the ind...
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Tuesday, Gilead Sciences Inc (NASDAQ: GILD) reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70 . Sales increased 6% year over year to $7.57 billion, beating the consen...
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.
GILD Stock Rises on Strong Quarterly Results
GILD Stock Rises on Strong Quarterly Results
Nasdaq 100: Treasury Yields Soar, Pressuring US Stocks—Tesla and Gilead Defy the Trend
US stock market declines as CPI data fuels Fed uncertainty. Nasdaq 100 struggles, but Tesla and Gilead Sciences defy the broader weakness.
Gilead Sciences Inc (GILD) Trading 6.86% Higher on Feb 12
Gilead Sciences Inc (GILD) Trading 6.86% Higher on Feb 12
Gilead Sciences (GILD) Stock Surge: Key Reasons Explained
Gilead Sciences (GILD) Stock Surge: Key Reasons Explained
Why Gilead Sciences Stock Is Jumping Today
Gilead Sciences (GILD) Surges Over 8% on Strong Q4 Earnings
Gilead Sciences (GILD) Surges Over 8% on Strong Q4 Earnings
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of Gilead Sciences, Inc . (NASDAQ: GILD) rose sharply during Wednesday's session after the company repo...